MedTrace Logo

Travoprost Ophthalmic Topical Cream for Open-angle Glaucoma or Ocular Hypertension

NCT06152861 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 250

Last updated 2023-12-06

No results posted yet for this study

Summary

The goal of this clinical trial is to learn about the safety of Travoprost Ophthalmic Topical Cream and how well it works in lowering high intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).

A low dose, medium dose and high dose of Travoprost Ophthalmic Topical Cream will be compared to timolol maleate ophthalmic solution, 0.5% and to travoprost ophthalmic solution, 0.004%.

Conditions

Interventions

DRUG

Travoprost Ophthalmic Topical Cream low-dose

travoprost ophthalmic topical cream low-dose once daily in the evening to both eyes

DRUG

Travoprost Ophthalmic Topical Cream mid-dose

travoprost ophthalmic topical cream mid-dose once daily in the evening to both eyes

DRUG

Travoprost Ophthalmic Topical Cream high-dose

travoprost ophthalmic topical cream high-dose once daily in the evening to both eyes

DRUG

Timolol maleate ophthalmic solution, 0.5%

timolol maleate ophthalmic solution, 0.5% twice daily (morning \& evening) to both eyes

DRUG

Travoprost Ophthalmic Solution, 0.004%

travoprost ophthalmic solution, 0.004% once daily in the evening to both eyes

Sponsors & Collaborators

  • Glaukos Corporation

    lead INDUSTRY

Principal Investigators

  • Study Director · Glaukos Corporation

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-15
Primary Completion
2024-08-31
Completion
2024-08-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06152861 on ClinicalTrials.gov